Sara Previtali

Ospedali Riuniti di Bergamo, Bergamo, Lombardy, Italy

Are you Sara Previtali?

Claim your profile

Publications (2)7.62 Total impact

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: To evaluate whether the presence of antiphospholipid antibodies in lymphoma patients influences their response to treatment, and their rate of thromboembolic complications, we followed up 100 consecutive patients with different lymphomas, who underwent measurement of lupus anticoagulants and anticardiolipin antibodies at diagnosis. In all, 27 patients had lupus anticoagulants and/or anticardiolipin antibodies. This prevalence was significantly higher than in a group of 100 age- and sex-matched normal control subjects (8%; P=0.0008, odds ratio 4.25, 95% confidence interval, 1.82-9.92). At diagnosis, antiphospholipid-positive and -negative patients were similar with respect to age, sex, type and staging of lymphomas. During follow-up, the rate of thrombosis was significantly higher in patients with (5.1% patients/year) than without (0.75% patients/year) antiphospholipid antibodies. The two groups were similar with respect to relapse and death rate. In conclusion, antiphospholipid antibodies are associated with lymphomas. Their determination is useful to identify patients at high risk to develop thrombotic complications, but not to predict treatment outcome or disease prognosis.
    The Hematology Journal 02/2004; 5(4):341-6. · 1.86 Impact Factor
  • Sara Previtali, Tiziano Barbui, Monica Galli
    [Show abstract] [Hide abstract]
    ABSTRACT: We performed a case-control study to assess whether anti-beta2-glycoprotein I and anti-prothrombin antibodies are independent risk factors of thrombosis. Cases were 79 patients with arterial and/or venous thrombosis without lupus anticoagulants, anticardiolipin antibodies and systemic lupus erythematosus; controls were 85 normal subjects. The prevalences and titers of IgG and IgM anti-beta2-glycoprotein I and anti-prothrombin antibodies were similar in both groups. Cases were analyzed with respect to the arterial or venous type of thrombosis and to the presence of congenital or acquired risk factors for thrombosis: no statistically significant relationships with the presence of anti-beta2-glycoprotein I and anti-prothrombin antibodies were found. Our data indicate that anti-beta2-glycoprotein I and anti-prothrombin antibodies are not risk factors for thrombosis independent of lupus anticoagulants and anticardiolipin antibodies. Their measurement, therefore, is not warranted in the laboratory screening of patients with arterial and/or venous thrombosis.
    Thrombosis and Haemostasis 12/2002; 88(5):729-32. · 5.76 Impact Factor